Published in J Hepatol on April 23, 2009
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization. World J Gastroenterol (2012) 0.96
Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol (2015) 0.94
Portal vein thrombosis. J Clin Exp Hepatol (2015) 0.92
Etiology and Complications of Portal Vein Thrombosis. Viszeralmedizin (2014) 0.88
What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. World J Gastroenterol (2012) 0.86
Viral cirrhosis: an overview of haemostatic alterations and clinical consequences. Mediterr J Hematol Infect Dis (2009) 0.85
Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients. BMC Gastroenterol (2011) 0.84
Portal vein thrombosis: a predictable milestone in cirrhosis? J Hepatol (2009) 0.84
Portal vein thrombosis after hepatectomy. World J Surg (2014) 0.84
Therapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosis. World J Hepatol (2015) 0.83
Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhotic patients with non-tumoral portal vein thrombosis: a hypothesis. Med Sci Monit (2012) 0.81
Role of D-dimer in the Development of Portal Vein Thrombosis in Liver Cirrhosis: A Meta-analysis. Saudi J Gastroenterol (2015) 0.80
Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis. World J Gastroenterol (2014) 0.78
Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis. Medicine (Baltimore) (2015) 0.78
A single hospital study on portal vein thrombosis in cirrhotic patients - clinical characteristics & risk factors. Indian J Med Res (2014) 0.78
Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. World J Gastrointest Oncol (2016) 0.77
Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis. World J Hepatol (2015) 0.77
Portal vein thrombosis in cirrhosis. J Clin Exp Hepatol (2013) 0.77
Management of portal vein thrombosis in cirrhotic patients. Mediterr J Hematol Infect Dis (2009) 0.77
Low molecular weight heparin in portal vein thrombosis of cirrhotic patients: only therapeutic purposes? ScientificWorldJournal (2014) 0.77
Association between D-dimer level and portal venous system thrombosis in liver cirrhosis: a retrospective observational study. Int J Clin Exp Med (2015) 0.76
Spontaneous bleeding or thrombosis in cirrhosis: What should be feared the most? World J Hepatol (2015) 0.76
Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS). J Acquir Immune Defic Syndr (2013) 0.76
Impact of sustained virus elimination on natural anticoagulant activity in patients with chronic viral hepatitis C. Bosn J Basic Med Sci (2013) 0.75
Spontaneous resolution of portal vein thrombosis in cirrhosis: where do we stand, and where will we go? Saudi J Gastroenterol (2014) 0.75
Extrahepatic portal vein obstruction and portal vein thrombosis in special situations: Need for a new classification. Saudi J Gastroenterol (2015) 0.75
[Portal vein thrombosis in a type 1 autoimmune hepatitis]. Pan Afr Med J (2013) 0.75
Precaution against postoperative venous complications after major hepatectomy using the pedicled omental transposition flap: Report of two cases. Int J Surg Case Rep (2014) 0.75
Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol (2017) 0.75
Liver transplant recipients with portal vein thrombosis receiving an organ from a high-risk donor are at an increased risk for graft loss due to hepatic artery thrombosis. Transpl Int (2016) 0.75
Anticoagulation in cirrhosis: a new paradigm? Clin Mol Hepatol (2017) 0.75
Efficacy and Safety of Direct-Acting Oral Anticoagulants Use in Acute Portal Vein Thrombosis Unrelated to Cirrhosis. Gastroenterology Res (2017) 0.75
Portal vein thrombosis in patients with cirrhosis. Gastroenterol Rep (Oxf) (2017) 0.75
Haemostatic Profile of Patients with Chronic Liver Disease- its Correlation with Severity and Outcome. J Clin Diagn Res (2017) 0.75
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res (2013) 2.84
Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord (2006) 2.74
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol (2005) 2.50
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2014) 2.47
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
Management of alcohol dependence in patients with liver disease. CNS Drugs (2013) 2.35
Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol (2014) 2.21
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis (2014) 2.17
Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol (2009) 2.17
Mental illness in homicide-suicide: a review. J Am Acad Psychiatry Law (2012) 2.16
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol (2009) 2.11
Different Antibiotic No Culture Eradicating (DANCE) strategy: an easy way to manage H. pylori eradication. Dig Liver Dis (2012) 2.11
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis (2013) 2.03
Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol (2011) 1.98
Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol (2005) 1.82
Chronic compensatory increase in ulnar flow and accelerated atherosclerosis after radial artery removal for coronary artery bypass. J Thorac Cardiovasc Surg (2005) 1.82
High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes (2010) 1.74
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Acute cryptogenic liver failure in an untreated coeliac patient: a case report. Eur J Gastroenterol Hepatol (2005) 1.65
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol (2006) 1.62
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol (2013) 1.62
The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord (2013) 1.62
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Endometriosis, need for a multidisciplinary clinical setting: the internist's point of view. Intern Emerg Med (2010) 1.53
Image-enhanced endoscopy with I-scan technology for the evaluation of duodenal villous patterns. Dig Dis Sci (2012) 1.52
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis. J Clin Gastroenterol (2003) 1.48
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) (2011) 1.45
Inverse correlation between serum free IGF-I and IGFBP-3 levels and blood pressure in patients affected with type 1 diabetes. Cytokine (2006) 1.44
Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud (2010) 1.43
Suicide in bipolar disorder: Risks and management. CNS Spectr (2006) 1.43
Integration of suicidology with general medicine: an obligation to society. Patient Educ Couns (2011) 1.42
The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest Endosc (2005) 1.41
Shibari: double hanging during consensual sexual asphyxia. Arch Sex Behav (2012) 1.39
Ten-year Echo-Doppler evaluation of forearm circulation following radial artery removal for coronary artery bypass grafting. Eur J Cardiothorac Surg (2005) 1.38
Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol (2008) 1.38
Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke (2004) 1.36
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2012) 1.35
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol (2002) 1.32
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest (2007) 1.32
Psychometric properties of the stagnation scale in medication overuse headache patients. J Headache Pain (2015) 1.29
The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25
Suicidal risk in antidepressant drug trials. Arch Gen Psychiatry (2006) 1.24
Parathyroid hormone levels 4 hours after surgery do not accurately predict post-thyroidectomy hypocalcemia. Surgery (2006) 1.20
Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog (2013) 1.19
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol (2005) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. Gastroenterology (2007) 1.17
CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis (2008) 1.15
Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet (2001) 1.15
Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol (2003) 1.15
Extragastric diseases and Helicobacter pylori. Helicobacter (2013) 1.14
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer (2014) 1.13
The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr Protein Pept Sci (2003) 1.13
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer (2013) 1.12
Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all. J Hepatol (2009) 1.12
Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol (2007) 1.12
Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis (2013) 1.12
Single-sample preparation for simultaneous cellular redox and energy state determination. Anal Biochem (2003) 1.12
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2010) 1.11
Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget (2011) 1.11
Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol (2010) 1.11
Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol (2007) 1.09
"Wait and see" policy for early hepatocellular carcinoma. J Hepatol (2013) 1.09
Intraoperative PTH monitoring during parathyroidectomy: the need for stricter criteria to detect multiglandular disease. Langenbecks Arch Surg (2008) 1.08
Sequential or combined treatment? That is the question. Radiology (2014) 1.07
Polymyalgia rheumatica in 2011. Best Pract Res Clin Rheumatol (2012) 1.05
Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol (2008) 1.05
Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol (2009) 1.05
Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D (2015) 1.04
Regional cerebral hypoperfusion in patients with celiac disease. Am J Med (2004) 1.03
No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care (2010) 1.03
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2011) 1.02
Isolation and characterization of hepatic stem cells, or "oval cells," from rat livers. Methods Mol Biol (2009) 1.02
Therapeutic implications of mesenchymal stem cells in liver injury. J Biomed Biotechnol (2011) 1.02
Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica (2008) 1.01